ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 1801 • ACR Convergence 2023

    Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study

    Ioanna Minopoulou1, Koray Tascilar2, Giulia Corte1, Melek Yalcin Mutlu1, Katja Schmidt2, Daniela Bohr1, Fabian Hartmann2, Bernhard Manger2, Arnd Kleyer3, David Simon1, Thomas Harrer2, Georg Schett4 and Filippo Fagni1, 1Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3University Hospital Erlangen, Erlangen, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
  • Abstract Number: 2305 • ACR Convergence 2023

    Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus

    Dr Hiba Khogali1, Ghada Al‐Bluwi2, Virgie Guy2 and Ali Al Dhanhani3, 1Tawam Hospital, Al Ain, United Arab Emirates, 2College of Medicine, UAE University, Al Ain, United Arab Emirates, 3UAE University, Al Ain, United Arab Emirates

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
  • Abstract Number: 0203 • ACR Convergence 2023

    Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization

    Zachary Wallace1, Aaron Wu2, Shruthi Srivatsan2, Naomi Patel2, Jeffrey Sparks3, Eli Miloslavsky2, Hyon K. Choi4, Peter Merkel5, John Stone6 and Emily Hyle2, 1Massachusetts General Hospital, Newton, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 4Massachusetts General Hospital and Harvard Medical School, Lexington, MA, 5University of Pennsylvania, Philadelphia, PA, 6Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
  • Abstract Number: 0588 • ACR Convergence 2023

    Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry

    Augustine Jose1, Aishwarya Gopal1, Mamatha Gorijavolu1, Anna C Das2, Jagan Babu K L1, Amrita Nayak1, Chengappa Kavadichanda1 and Molly Mary Thabah1, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 2St.Johns National Academy of Health Sciences, Bengaluru, India

    Background/Purpose: Rituximab (RTX) is increasingly being employed to treat refractory systemic lupus erythematosus(SLE). Though the drug is effective there is a high risk of adverse…
  • Abstract Number: 1324 • ACR Convergence 2023

    Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK

    Roxanne Cooksey1 and Ernest Choy2, 1Cardiff University, Cardiff, United Kingdom, 2Section of Rheumatology, Cardiff University, Cardiff, United Kingdom

    Background/Purpose: Biologic therapy has revolutionised the treatment of rheumatoid arthritis (RA). Randomised control trials have shown that IL-6 inhibitors are superior to adalimumab, a TNF…
  • Abstract Number: 1856 • ACR Convergence 2023

    Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

    Kathlyn Camargo Macias1, Ravi Shahu Khal1, Ariail Schmitz2, Kathleen McCabe1, Taylor Kann1, Marilyn Mosquera3 and Ashwini Komarla4, 1University of Central Florida, Orlando, FL, 2University of Central Florida, St. Cloud, FL, 3University of Central Florida, Casselberry, FL, 4ORLANDO VAMC, Orlando, FL

    Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
  • Abstract Number: 2309 • ACR Convergence 2023

    Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus

    Luis Vega Sevilla1, Oscar E. Alvarez-González2, Janett Riega-Torres3, Cassandra Michele Skinner-Taylor3, Diana Carolina Rubio Torres4, Lucio Vera Cabrera5, Dionicio A. Galarza-Delgado6, Jesus Alberto Cardenas-De la Garza7, Rodrigo J. Castillo-de la Garza5, Mario Alberto Aguilera Valenciano5, wendy Escalante5 and Hector Guerra8, 1Hospital Universitario UANL, Garcia, Mexico, 2Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 4Faculty of Medicine and University Hospital Dr. José Eleuterio González, UANL, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Mexico, 6Hospital Universitario UANL, Monterrey, Mexico, 7Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 8Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with epithelial defects and disrupted intestinal barrier, risking bacterial translocation, and promoting systemic inflammation, known as dysbiosis, which…
  • Abstract Number: 0204 • ACR Convergence 2023

    Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases

    Claire Rempenault1, Cedric Lukas2, Léa Tardivon3, Claire Daien4, Bernard G. Combe5, Philippe GUILPAIN3 and JACQUES MOREL6, 1Universary Hospital of Montpellier, Montpellier, France, 2CHU Montpellier, Montpellier, France, 3University of Montpellier, Montpellier, France, 4University Hospital, Montpellier, France, 5Department of Rheumatology, Montpellier University, Montpellier, France, 6Protocole thérapeutique immuno-rhumatologie, Montpellier, France

    Background/Purpose: Literature data on the increased risk of severe infection regarding hypogammaglobinemia related to RTX in IMID are controversial and sparse. We proposed to evaluate…
  • Abstract Number: 0663 • ACR Convergence 2023

    Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis

    Saman Tanveer, Chun Pan and Faria Sami, John H. Stroger Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Connective tissue disorders, including systemic sclerosis (SSc), are associated with an increased risk of infections. Infections are the most common diagnosis during hospitalizations and…
  • Abstract Number: 1334 • ACR Convergence 2023

    Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses

    Marina Birck1, Luck Lukusa2, Michal Abrahamowicz3, Gilles Boire4, Denis Choquette5, Walter P. Maksymowych6 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2RI-MUHC, Montreal, QC, Canada, 3McGill University, Verdun, QC, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 6University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Treatment safety, particularly malignancy and infections, is an important issue for biologics; hence, surveillance and analyses comparing biosimilar versus bio-originator use in the real…
  • Abstract Number: 1928 • ACR Convergence 2023

    Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies

    Cristina Calomarde Gomez1, Raquel Ugena García1, Julia Valera2, Melisa Mena2, Maria Esteve2, Irma Casas2, jose Antonio Dominguez-Benitez2, lidia Carabias-Ane2, isaac Nuño-Ruiz2, Cristina ramo-Tello2, Javier Santesmases2, Lourdes Mateo Soria3 and Melania Martinez Morillo1, 1Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 3HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain

    Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
  • Abstract Number: 2312 • ACR Convergence 2023

    Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis

    Saman Tanveer and Chun Pan, John H. Stroger Jr. Hospital of Cook County, Chicago, IL

    Background/Purpose: Immunosuppressive therapy is the cornerstone of management in patients with systemic lupus erythematosus (SLE). Patients on immunosuppressive therapy are at increased risk of developing…
  • Abstract Number: 0205 • ACR Convergence 2023

    Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy

    Jamie Chieh Lo1, Ying-Nan Tsai2, Cheng-Hao Tseng3, Yao-Chun Hsu4 and Song-Chou Hsieh5, 1School of Medicine, I-Shou University, Kaohsiung, Taiwan, 2Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, 3Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, 4I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, 5National Taiwan University Hospital, Taipei, Taiwan

    Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
  • Abstract Number: 0680 • ACR Convergence 2023

    Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study

    Johanne LIBERATORE1, Yann Nguyen2, Jerome HADJADJ3, Pascal Cohen4, Luc Mouthon5, Xavier Puéchal6, Loic Guillevin7 and Benjamin Terrier8, 1Centre Hospitalier ANGOULEME, Angouleme, France, 2Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, 3Cochin Hospital, Paris, France, 4CHU Cochin, Paris, France, 5Hopital Cochin - Paris University, Paris, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 7University Paris Descartes, Paris, France, 8Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: B-cell depletion induced by rituximab (RTX) in ANCA-associated vasculitis (AAV) is a risk factor for hypogammaglobulinemia. Aggregating data on the kinetics of gammaglobulin levels…
  • Abstract Number: 1445 • ACR Convergence 2023

    SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort

    Iñigo Rúa-Figueroa1, Maria Jesus Garcia de Yebenes2, JULIA MARTINEZ BARRIO3, Maria Galindo-Izquierdo4, Jaime Calvo- Alén5, Antonio Fernandez-Nebro6, Raúl Menor-Almagro7, Eva Tomero Muriel8, Mercedes Freire González9, Clara Sanguesa Gomez10, Loreto Horcada11, Ricardo Blanco12, Esther Uriarte Isacelaya13, Maria J. García-Villanueva14, Javier Narvaez15, Jose Rosas16, Silvia Gómez-Sabater17, Clara Moriano Morales18, Jose Luis Andreu-Sánchez19, Vicente Torrente-Segarra20, Elena Aurrecoechea Aguinaga21, Ana Pérez Gómez22, Javier Novoa Medina23, Eva Salgado-Pérez24, Nuria Lozano Rivas25, Carlos Montilla-Morales26, maria esther ruiz-lucea27, Marta Arévalo Salaet28, Carlota Iñíguez29, Lorena Expósito30, Mónica Ibáñez-Barceló31, Gema Bonilla32, Irene Carrión-Barberà33, Celia Erausquin34, Angela Pecondon-Español35, Francisco Javier Toyos Sáenz de Miera36, Tatiana Cobo37, Alejandro Muñoz38, Jorge Juan Fragio39, Jose Eloy Oller40, Beatriz Tejera Segura23 and Jose-Maria Pego-Reigosa41, 1Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, 2InMusc, Madrid, Spain, 3Rheumatology, Gregorio Marañon University Hospital, Madrid, Spain, 4Rheumatology, University Hospital of 12 de Octubre, Madrid, Spain, 5Rheumatology, Bioaraba Research Unit, Hospital Universitario Araba, Vitoria, Spain, 6Hospital Regional Universitario de Málaga, Malaga, Spain, 7Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, 8Rheumatology, Hospital La Princesa, Madrid, Spain, 9Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, 10Severo Ochoa Hospital, Madrid, Spain, 11Hospital de Navarra, Pamplona, Spain, 12Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 13Rheumatology, University Hospital of Donosti, San Sebastián, Spain, 14Hospital Ramón y Cajal, Madrid, Spain, 15Hospital Universitario de Bellvitge, Barcelona, Spain, 16Hospital Marina Baixa, Alicante, Spain, 17Rheumatology Department, Dr. Balmis University General Hospital, Alicante. Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain, 18Rheumatology, Hospital Universitario de León, León, Spain, 19Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, 20Department of Rheumatology, Hospital de Sant Joan Despí Moises Broggi,, Sant Joan Despí, Spain, 21Department of Rheumatology, Hospital Sierrallana, Torrelavega, Spain, 22Rheumatology, Hospital Principe de Asturias, Alcalá de Henares, Spain, 23Complejo Hospitalario Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain, 24Department of Rheumatology, University Hospital of Ourense, Ourense, Spain, 25Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 26Rheumatology, University Hospital of Salamanca, Salamanca, Spain, 27Hospita de Basurto, Bilbao, Spain, 28Rheumatology Department University Hospital Parc Taulí, Sabadell, Spain, 29Hospital Lucus Augusti, Lugo, Spain, 30Rheumatology Unit, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain, 31Rheumatology, Hospital Universitari Son Llàtzer, Palma de Mallorca, Spain, 32Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, 33Hospital del Mar, Barcelona, Spain, 34Rheumatology Department Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, 35Hospital Miguel Servet, Zaragoza, Spain, 36Hospital Virgen Macarena, Sevilla, Spain, 37Department of Rheumatology, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, 38Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, 39Hospital General Universitario Valencia, Valencia, Spain, 40Hospital Doctor Peset, Valencia, Spain, 41Rheumatology, Hospital do Meixoeiro, Vigo, Spain

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of serious infections that varies with the severity of the disease, use of immunosuppressives,…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology